Print Friendly, PDF & Email

NCT/Study#

NCT02744287 /

BP-012

A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors

DISEASE GROUP:

Phase 1 Clinical Trials

current phase:

Phase I/II

STUDY STATUS:

Accepting Patients

Location:

Hackensack, NJ

For More information:

Call 201-518-3587